ARMC10

Across TCGA pan-cancer cohorts, ARMC10 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARMC10 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARMC10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARMC10 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where ARMC10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.674	0.959	.001	15	view →
CCRCC	DFS	Tertile	III,IV	0.198	1.000	.024	10	view →
LSCC	OS	Median	II,III,IV	1.000	0.885	.022	9	view →
LUAD	DFS	Tertile	II,III,IV	0.968	0.771	.025	7	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.917	.046	6	view →
HNSC	DFS	Median	III,IV	0.722	0.838	.044	2	view →
GBM	OS	Median	All	0.620	0.447	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARMC10–PDAC (DFS)

Open the PDAC breakdown →